Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

Zodasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins across all dose levels at Week 24 Data presented at European Atherosclerosis Society 92nd Congress and

Related Keywords

Vince Anzalone ,Robert Rosenson ,Brian Ritchie ,Coll Cardiol ,Kendy Guarinoni ,Gugliucciaj Clin ,Linkedin ,Nasdaq ,Lifesci Advisors ,Arrowhead Pharmaceuticals Inc ,European Atherosclerosis Society ,Exchange Commission ,Lifesci Communications ,Icahn School Of Medicine At Mount Sinai ,Arrowhead Pharmaceuticals ,New England Journal ,Bruce Given ,Icahn School ,Mount Sinai ,Principal Investigator ,Atherosclerosis Society ,Congress May ,Late Breaker Session ,New Therapeutic Agents ,Harbor Statement ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Sci Advisors ,Sci Communications ,Ihr Portfolio ,